293 related articles for article (PubMed ID: 10955782)
1. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Mormont MC; Waterhouse J; Bleuzen P; Giacchetti S; Jami A; Bogdan A; Lellouch J; Misset JL; Touitou Y; Lévi F
Clin Cancer Res; 2000 Aug; 6(8):3038-45. PubMed ID: 10955782
[TBL] [Abstract][Full Text] [Related]
2. Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer.
Chevalier V; Mormont MC; Curé H; Chollet P
Oncol Rep; 2003; 10(3):733-7. PubMed ID: 12684651
[TBL] [Abstract][Full Text] [Related]
3. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
5. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
[TBL] [Abstract][Full Text] [Related]
6. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
[TBL] [Abstract][Full Text] [Related]
8. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
[TBL] [Abstract][Full Text] [Related]
9. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
Innominato PF; Giacchetti S; Bjarnason GA; Focan C; Garufi C; Coudert B; Iacobelli S; Tampellini M; Durando X; Mormont MC; Waterhouse J; Lévi FA
Int J Cancer; 2012 Dec; 131(11):2684-92. PubMed ID: 22488038
[TBL] [Abstract][Full Text] [Related]
10. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the characteristics of the circadian rest-activity rhythm of cancer in-patients.
Pati AK; Parganiha A; Kar A; Soni R; Roy S; Choudhary V
Chronobiol Int; 2007; 24(6):1179-97. PubMed ID: 18075806
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
13. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Innominato PF; Giacchetti S; Moreau T; Bjarnason GA; Smaaland R; Focan C; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Poncet A; Spiegel D; Lévi F;
Cancer; 2013 Jul; 119(14):2564-73. PubMed ID: 23633399
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
[TBL] [Abstract][Full Text] [Related]
15. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
17. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Ortiz-Tudela E; Iurisci I; Beau J; Karaboue A; Moreau T; Rol MA; Madrid JA; Lévi F; Innominato PF
Int J Cancer; 2014 Jun; 134(11):2717-25. PubMed ID: 24510611
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
19. [Study of circadian rhythms of activity by actometry: preliminary results in 30 patients with metastatic colorectal cancer].
Mormont MC; De Prins J; Lévi F
Pathol Biol (Paris); 1996 Mar; 44(3):165-71. PubMed ID: 8761603
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
